Radiology Therapeutic Center S.R.L. — Clinical Trial Site

11 Registered trials

5 Currently recruiting

Organisation

Radiology Therapeutic Center S.R.L.

Location

Otopeni, Romania

Identifier

ORG-100040986

Address

Strada Oitelor Nr 7, 040278, Romania

Departments

Centrul de Radioterapie si Chimioterapie
Centrul de Radioterpaie si Chimioterapie
Medical Oncology Department
N/A
Oncologie
Oncologie Clinica
Oncology

Clinical trials at this site (11)

Search interface

A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC… Ended

2023-507475-21-00 Lung Cancer, Non-Small Cell 10 2021-01-18
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
A study to investigate the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of GSK4524101 alone or with nira… Ended

2024-520197-36-00 Neoplasms 7